Madrigal Pharmaceuticals to Participate in the H.C. Wainwright & Co. 8th Annual MASH Investor Conference

MDGL 10.02.2024

Full Press ReleaseSEC FilingsOur MDGL Tweets

About Gravity Analytica

Recent News

  • 01.15.2025 - 43rd Annual J.P. Morgan Healthcare Conference
  • 01.13.2025 - Madrigal Pharmaceuticals Announces Preliminary* Fourth-Quarter and Full-Year 2024 Net Sales, Year-End Cash and Total Patients on Rezdiffra
  • 01.03.2025 - Madrigal Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Recent Filings

  • 01.17.2025 - 4 Statement of changes in beneficial ownership of securities
  • 01.17.2025 - 144 Report of proposed sale of securities
  • 01.13.2025 - EX-99.1 EX-99.1

CONSHOHOCKEN, Pa.,Oct. 02, 2024(GLOBE NEWSWIRE) --Madrigal Pharmaceuticals, Inc.(Nasdaq: MDGL) today announced the company will participate in a fireside chat at the H.C. Wainwright 8thAnnualMASH Virtual Investor Conferenceat2:00 P.M. ETonMonday, Oct. 7, 2024.

The fireside chat will be webcast live and may be accessedhereor by visiting Madrigal’s website’s Investor Relations Eventspage. A replay of the webcast will be available after the event.

AboutMadrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc.(Nasdaq: MDGL) is a biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of NASH. For more information, visitwww.madrigalpharma.com.

Investor ContactTina Ventura,[email protected]

Media ContactChristopher Frates,[email protected]

Primary Logo

Source: Madrigal Pharmaceuticals, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com